EdgarLookup

Contineum Therapeutics, Inc. — Insider Transactions

Form 4 filings by directors, officers, and 10%+ shareholders

SEC rules require corporate insiders — including directors, executive officers, and any shareholder owning more than 10% of a company's shares — to report changes in their ownership within two business days of a transaction. These disclosures are filed as Form 4. Open-market purchases (code P) are generally considered the most meaningful signal, as insiders are spending their own money.

Overview All Filings Annual Quarterly Insiders
Insider Title Type Shares Price Value Owns After Date
Watkins Tim CMO & Head of Development Option Exercise 3,611 $4.50 $16,250 3,611 Dec 29, 2025
Lorrain Daniel S. Chief Scientific Officer Sale 4,170 $12.23 $50,999 164,392 Dec 23, 2025
Lorrain Daniel S. Chief Scientific Officer Sale 1,010 $16.02 $16,180 168,562 Nov 25, 2024
Lorrain Daniel S. Chief Scientific Officer Sale 99 $17.05 $1,688 169,572 Nov 18, 2024
Huhn Stephen L. CMO & Sr VP, Clinical Dev. Option Exercise 12,800 $1.01 $12,928 12,800 Aug 13, 2024
Versant Vantage I, L.P. C 2,531 2,531 Apr 9, 2024